Home » Stocks » AMRN

Amarin Corporation Plc (AMRN)

Stock Price: $4.26 USD -0.09 (-2.07%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $4.24 -0.02 (-0.47%) May 13, 5:47 PM
Market Cap 1.72B
Revenue (ttm) 601.24M
Net Income (ttm) 927,000
Shares Out 394.77M
EPS (ttm) 0.00
PE Ratio 2,130.00
Forward PE 500.00
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.26
Previous Close $4.35
Change ($) -0.09
Change (%) -2.07%
Day's Open 4.36
Day's Range 4.16 - 4.48
Day's Volume 4,580,487
52-Week Range 3.36 - 9.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATE Amarin-Supported Resea...

1 week ago - GlobeNewsWire

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line.

2 weeks ago - Zacks Investment Research

Shares of Amarin Corp (NASDAQ:AMRN) rose 2.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 100.00% over the past year to ($0.00), which beat the...

2 weeks ago - Benzinga

Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Re...

2 weeks ago - GlobeNewsWire

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision...

2 weeks ago - GlobeNewsWire

VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, 3

3 weeks ago - GlobeNewsWire

DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior managemen...

3 weeks ago - GlobeNewsWire

Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy

3 weeks ago - GlobeNewsWire

The company's CEO announced his retirement.

1 month ago - The Motley Fool

John Thero to Retire as President and CEO on August 1, 2021

1 month ago - GlobeNewsWire

All three companies have enjoyed major growth catalysts since the start of 2021.

Other stocks mentioned: NNOX, NVTA
1 month ago - The Motley Fool

This biotech's heart medication could be wildly lucrative.

1 month ago - The Motley Fool

Reimbursement dossiers for first 10 countries to be filed in coming months

1 month ago - GlobeNewsWire

Amarin and Accelerate Diagnostics are healthcare companies with significant upside.

Other stocks mentioned: ISRG
1 month ago - The Motley Fool

The company won crucial regulatory approval in a massive new market.

1 month ago - The Motley Fool

The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The approval co...

1 month ago - Benzinga

Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studie...

1 month ago - GlobeNewsWire

HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included icosapent ethyl (Vascepa) in 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disea...

1 month ago - Benzinga

There are plenty of cheap stocks out there, but don't confuse inexpensive for undervalued; these 10 stocks under $10 should be avoided. The post 10 Cheap Stocks Under $10 That Don't Deserve Your Time or...

Other stocks mentioned: ARCO, CLNC, CXW, DHT, EBR, FRO, ITUB ...
1 month ago - InvestorPlace

Amarin Corporation plc (NASDAQ: AMRN) has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Con...

1 month ago - Benzinga

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without...

1 month ago - GlobeNewsWire

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

2 months ago - Zacks Investment Research

The drugmaker topped analysts' top- and bottom-line expectations despite challenges from a generic rival and the pandemic.

2 months ago - The Motley Fool

Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact

2 months ago - GlobeNewsWire

With the crazy bullishness in the market, you can't find too many discounted plays. However, these sleeper stocks might just give your portfolio the kickstart it needs in 2021.

Other stocks mentioned: AHEXY, EATBF, KELYA, LLNW, OPK, SKX, SWCH
2 months ago - InvestorPlace

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is sched...

2 months ago - GlobeNewsWire

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management...

2 months ago - GlobeNewsWire

If you're looking for hot stocks to buy, it makes sense to focus your search on growth companies. Here are 10 picks that ought to stay hot.

Other stocks mentioned: BATRA, BATRK, DKNG, ELY, IAC, SSYS, VSAT ...
3 months ago - InvestorPlace

The approval process for its top drug is starting in two major Asian markets.

3 months ago - The Motley Fool

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosap...

3 months ago - GlobeNewsWire

It's been a long and painful path to market success for Amarin. Legal roadblocks devastated the share price and brought generics to market much sooner than expected.

3 months ago - Seeking Alpha

It's all about the incentives.

3 months ago - The Motley Fool

Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study

3 months ago - GlobeNewsWire

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascular ...

3 months ago - GlobeNewsWire

These stocks have one obvious thing in common.

Other stocks mentioned: BLUE, NKTR
3 months ago - The Motley Fool

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in...

3 months ago - GlobeNewsWire

Investors holding shares in these two companies need to practice patience.

Other stocks mentioned: CCL
3 months ago - The Motley Fool

Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

4 months ago - Seeking Alpha

Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019

4 months ago - GlobeNewsWire

Down 77% in 2020, Amarin's stock should zoom higher once Vascepa obtains European approval.

4 months ago - The Motley Fool

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is sched...

4 months ago - GlobeNewsWire

Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

These companies are eager to say good riddance to the year that was.

Other stocks mentioned: ICPT, IVR, NGL, NXTC, PBF, SNDL, TCDA ...
4 months ago - The Motley Fool

Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was annou...

Other stocks mentioned: BMRN
4 months ago - GuruFocus

REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers

4 months ago - GlobeNewsWire

VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reac...

5 months ago - GlobeNewsWire

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA C...

5 months ago - GlobeNewsWire

These are the stocks seeing the most insider buying this week

YouTube video

Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.

Other stocks mentioned: BIIB, KDP, LMNX
5 months ago - CNBC Television

Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)

5 months ago - Seeking Alpha

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commerciali... [Read more...]

Industry
Biotechnology
IPO Date
Apr 1, 1993
CEO
John Thero
Employees
1,000
Stock Exchange
NASDAQ
Ticker Symbol
AMRN
Full Company Profile

Financial Performance

In 2020, Amarin's revenue was $614.06 million, an increase of 42.89% compared to the previous year's $429.76 million. Losses were -$18.00 million, -20.51% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.25, which is an increase of 140.61% from the latest price.

Price Target
$10.25
(140.61% upside)
Analyst Consensus: Buy